I last reviewed Abbvie (ABBV) in my November 12, 2022 post at which time I expressed my relief that ABBV was deleveraging. Now, however, ABBV's debt will increase because of its recently announced ImmunoGen (IMGN) acquisition. I am, therefore, not increasing my Abbvie exposure for reasons presented herein. In my previous post, I also commented [...]
This FFJ Portfolio - November 2023 report is an overview of my recent investment activity. What a difference in less than a month! The value of the holdings within the FFJ Portfolio increased ~$94,609 CDN and ~$363,753 USD from the end of October to the end of November. I, however, did not acquire additional shares [...]
Following the November 20 market close, A released its Q4 and FY2023 results and Q1 and FY2024 guidance. Despite the challenging market conditions, Agilent forecasts strong cash flow in FY2024. When I reviewed Agilent Technologies (A) in my August 16 post, it had just released its Q3 and YTD2023 results and revised FY2023 guidance. At [...]
Zoom Video Communications (ZM) raises guidance for the 3rd time in FY24. With the release of Q3 and YTD2024 results on November 20 and revised guidance, I revisit ZM and disclose the purchase of additional shares in one of the 'Core' accounts within the FFJ Portfolio. NOTE: Do not confuse ZM with ZoomInfo Technologies Inc. [...]
After several suggestions over a few years (I work quickly), I have added a 'Books' page. On this page, I share a selection of books I have found to be entertaining and/or thought-provoking. I have also added FFJ Portfolio Holdings and FFJ Portfolio Monthly Dividend Income links at the top of the website. I try [...]
When I last reviewed Copart (CPRT) in this September 16, 2023 post, it had just released its FY2023 results. On October 10, Copart announced that it is transforming the auction world with the acquisition of a majority interest in Purple Wave, an online heavy equipment auction company. Now that we have CPRT's Q1 2024 financial [...]
The time to invest in great companies is when they fall out of favour. Buy Thermo Fisher Scientific (TMO) while it faces short-term headwinds. I last reviewed TMO in this brief September 8 post. At the time, shares were reasonably valued at ~$514 based on earnings guidance. On October 25, however, TMO released its Q3 [...]
In my November 9 guest post at Dividend Power, I suggest investors buy Nike (NKE) stock when investor fear returns. Consumers in various global economies are feeling the effects of higher inflation and the higher interest rates central banks have been using to combat higher inflation. It remains to be seen the extent to which [...]
This post is in response to inquiries about recommended reading. Other recommendations will be provided at a later date. On May 25, 2016, the 'work thing' ended and I got my life back. This is when I made a commitment to exercise more regularly. I have kept that commitment and typically have daily ~2-hour high-intensity [...]
Chevron's (CVX) share price has slid from its early November 2022 ~$190 peak to ~$147 following the release of its Q3 2023 report that showed rising expenses from overseas projects, most notably in Kazakhstan. The world, however, needs energy and CVX is positioning itself to play a key role in helping meet the world's future [...]